Page last updated: 2024-11-05

c.i. solvent yellow 56

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

C.I. Solvent Yellow 56: not a carcinogen [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Solvent yellow 56 : An azobenzene that is N,N-diethylaniline substituted at position 4 by a phenylazo group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID17204
CHEMBL ID3561103
CHEBI ID91087
SCHEMBL ID332067
MeSH IDM0050527

Synonyms (62)

Synonym
einecs 219-616-8
benzenamine, n,n-diethyl-4-(phenylazo)-
n,n-diethyl-p-(phenylazo)aniline
aniline, n,n-diethyl-p-(phenylazo)-
fat yellow ggn
nsc 102374
ccris 6922
c-299
diethylaminoazobenzene
4-(diethylamino)azobenzene
diethyl yellow
2481-94-9
c.i. 11021
sudan yellow ggn
p-(diethylamino)azobenzene
nsc-102374
n,n-diethyl-4-(phenylazo)aniline
4-phenylazo-n,n-diethylaniline
ceres yellow ggn
n,n-diethyl-4-(phenylazo)benzenamine
c.i. solvent yellow 56
nsc102374
n,n-diethyl-4-aminoazobenzene
benzenamine,n-diethyl-4-(phenylazo)-
waxoline yellow ed
D1126
NCIOPEN2_006878
n,n-diethyl-4-phenyldiazenylaniline
solvent yellow 56
5e973680s8 ,
unii-5e973680s8
benzenamine, n,n-diethyl-4-(2-phenyldiazenyl)-
4-diethylaminoazobenzene
FT-0634313
4-(phenylazo)-n,n-diethylaniline
aizen sot yellow 1
ci solvent yellow 56
4-(n,n-diethylamino)azobenzene
ci 11021
SCHEMBL332067
CHEBI:91087
n,n-diethyl-4-(phenyldiazenyl)aniline
AKOS024302281
dtxsid8041745 ,
dtxcid6021745
tox21_303805
cas-2481-94-9
NCGC00356965-01
W-109792
CHEMBL3561103
mfcd00009043
(e)-n,n-diethyl-4-(phenyldiazenyl)aniline
Q60279
87986-73-0
D89789
n,n-diethyl-4-(2-phenyldiazen-1-yl)aniline
AS-56893
AKOS037645078
solventyellow56
CAA48194
n,n-diethyl-4-((e)-phenyldiazenyl)aniline
DTXSID901024696
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
dyenull
mutagenAn agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
azobenzenesAny member of the wide class of molecules that share the core azobenzene structure, comprising two phenyl rings linked by a N=N double bond, which may have different functional groups extending from the rings.
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
substituted aniline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency0.50250.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency70.97990.002541.796015,848.9004AID1347399
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency30.89563.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency0.20780.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency54.94100.173734.304761.8120AID1346924
SMAD family member 3Homo sapiens (human)Potency54.94100.173734.304761.8120AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency13.15170.000714.592883.7951AID1259368; AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency4.18030.000221.22318,912.5098AID1259243; AID1259247; AID1259381
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency76.95880.013326.981070.7614AID1346978
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency5.45700.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency40.23090.000417.946075.1148AID1346784; AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency0.11330.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency17.48910.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency1.53730.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency1.36850.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.25710.000229.305416,493.5996AID1259244; AID1259248; AID1259383
caspase-3Homo sapiens (human)Potency76.95880.013326.981070.7614AID1346978
thyroid stimulating hormone receptorHomo sapiens (human)Potency66.05580.001628.015177.1139AID1259385; AID1259395
Histone H2A.xCricetulus griseus (Chinese hamster)Potency126.79300.039147.5451146.8240AID1224845
histone deacetylase 9 isoform 3Homo sapiens (human)Potency24.49790.037617.082361.1927AID1259364; AID1259388
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.34380.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.34380.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (16.28)18.7374
1990's3 (6.98)18.2507
2000's10 (23.26)29.6817
2010's20 (46.51)24.3611
2020's3 (6.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.18 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.98 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]